Objective: Individuals with endogenous subclinical thyrotoxicosis (SCT) may subsequently require treatment for overt disease. We aimed to evaluate the frequency of progression to hyperthyroidism and factors influencing this outcome.
Design: This is a retrospective analysis of outcome in 96 consecutive patients (aged 16-91 years) diagnosed with SCT over a 6-year period. Individuals with secondary causes of TSH suppression were excluded. Mean follow-up was 3·8 years. The significance of age, gender, family history of thyrotoxicosis, symptoms at presentation, thyroid nodule(s) on clinical examination, entry TSH level, antithyroid antibody status and (99m) Tc pertechnetate thyroid imaging results on subsequent development of overt thyrotoxicosis was assessed.
Results: Progression to overt thyrotoxicosis was seen in 8% at 1 year, 16% at 2 years, 21% at 3 years and 26% at 5 years. Multivariate analysis determined that diagnosis as determined by scintiscan to be the only independent predictor of outcome (P = 0·003) with the cumulative percentage requiring therapy at 5 years being 9% for subclinical Graves' disease, 21% for multinodular goitre and 61% for the autonomous nodule subgroup.
Conclusions: Progression of SCT to overt hyperthyroidism occurred at a rate of 5-8% per year with disease aetiology, as determined by thyroid scintigraphy, significantly influencing risk of progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2265.2010.03908.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pattern and Predictors of Thyroid Dysfunction among Pediatric Endocrine Referrals at the Tertiary Care Center of Northern India: A Longitudinal Study.
Indian J Community Med
July 2024
Department of Endocrinology Sher-I Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
Article Synopsis
- Pediatric thyroid disorders are increasingly diagnosed, with subclinical hypothyroidism (SCH) being the most common, found in 39% of cases among children referred for evaluation.
- The study involved 241 treatment-naïve children under 18, where data was collected on various thyroid-related metrics, and treatment decisions were made based on clinical judgment with a follow-up over a year.
- Significant factors influencing treatment included age, gender, autoantibody positivity, and family history, indicating that autoimmunity and familial links play essential roles in managing SCH and highlight the need for ongoing surveillance for congenital hypothyroidism (CH).
New onset of Graves' disease after controlled ovarian stimulation: A case report and brief literature review.
Int J Gynaecol Obstet
October 2024
Medical Department, ASST Mantova, Mantua, Italy.
Article Synopsis
- A 40-year-old woman with no prior thyroid issues developed Graves' disease (GD) after undergoing controlled ovarian stimulation (OS) for infertility, despite normal thyroid function tests before the last cycle.
- Six weeks post-OS, she experienced severe hyperthyroidism with positive anti-thyrotropin receptor antibodies, confirming a GD diagnosis, and started anti-thyroid treatment.
- Thyroid function remained suboptimal after a year of treatment, leading to a recommendation to postpone further OS cycles until her thyroid condition improved, with possible consideration of surgery if she still wanted to become pregnant.
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients.
Endocr Relat Cancer
November 2024
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Pembrolizumab-related thyroid dysfunction may lead to better outcomes in early-stage triple-negative breast cancer (TNBC) patients undergoing preoperative therapy.
- The study compared outcomes (pathological complete response (pCR) and event-free survival (EFS)) among patients with and without this thyroid dysfunction, discovering that no significant differences in pCR and EFS were observed overall.
- Notably, patients who developed overt thyrotoxicosis had a higher pCR rate (85.7%) compared to others (42.1%), suggesting a potential link between this specific thyroid condition and improved treatment response.
Assessing the impact of short-term Lugol's solution on toxic nodular thyroid disease: a pre-post-intervention study.
Front Endocrinol (Lausanne)
August 2024
Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
Purpose: Preoperative iodine therapy in toxic nodular goiter (TNG) is discouraged as iodine may cause aggravation of hyperthyroidism. We aimed to examine if a short course of iodine treatment is safe to administer in TNG.
Methods: Patients with TNG (n=20) and subclinical to mild hyperthyroidism (free (f)T4 <30 pmol/L) without complicating illnesses were included in this pre-post-intervention study at Karolinska University Hospital.
Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection.
Diabetol Int
July 2024
Department of Diabetes and Endocrinology, Osaka Police Hospital, 10-31 Kitayama-Cho Tennojiku, Osaka, 543-0035 Japan.
There is growing evidence suggesting an association between severe acute respiratory coronavirus syndrome coronavirus 2 (SARS-CoV-2) infection and various extrapulmonary diseases since the advent of coronavirus disease 2019 (COVID-19) pandemic. However, case reports of fulminant type 1 diabetes mellitus (FT1D) following SARS-CoV-2 infection are limited. We encountered a 44-year-old Japanese woman who developed FT1D accompanied by subclinical thyrotoxicosis caused by autoimmune thyroid disease (AITD) approximately one week after SARS-CoV-2 infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!